Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FER | P16591 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008952 | 0.79 | LRRK2 (0.45) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL2203198 | 0.79 | LRRK2 (0.50) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL20505096 | 0.73 | MAPT (0.44) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL20723 | 0.73 | MAPT (0.44) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL7514332 | 0.72 | LRRK2 (0.41) | LRRK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19888 | 0.70 | MEN1 (0.50) | MAOAMAOBGSK3BCASP3MAPT | |
| SCHEMBL2995809 | 0.69 | GABRA1 (0.56) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL2782043 | 0.69 | NOS2 (0.39) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL6255304 | 0.69 | LRRK2 (0.58) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL2420711 | 0.69 | LRRK2 (0.90) | LRRK2MAOAMAOBPDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA, INC. | 2024-02-15 | — | — | US | claimed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | claimed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | claimed |
| EP-2102189-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-09-23 | — | — | EP | claimed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | claimed |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-10-16 | — | — | US | claimed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | claimed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | claimed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | claimed |
| EP-0737204-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1996-10-16 | — | — | EP | claimed |
| WO-1995015973-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| US-5262418-A | Laxatives, gastrointestinal disorders | TANSSEN PHARMACEUTICA N.V. (BE) | 1993-11-16 | — | — | US | claimed |
| US-5185335-A | Administer to mammals to stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-02-09 | — | — | US | claimed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | claimed |
| US-5079249-A | Serotine antagonists at 5-HT2 level, antiallergens, antihistamines | ADIR ET COMPAGNIE (FR) | 1992-01-07 | — | — | US | claimed |
| US-5071847-A | BIS (ARYL) ALKENE COMPOUNDS OF HOMOPIPERIDINES USEFUL AS SEROTONIN-ANTAGONISTS | ADIR ET COMPAGNIE (FR) | 1991-12-10 | — | — | US | claimed |
| EP-0445862-A2 | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-09-11 | — | — | EP | claimed |
| US-5028607-A | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 1991-07-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | LRRK2 392/4885MAOA 84/4885MAOB 92/4885 |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | IGLV6-57, TTR, MAP1LC3C | LRRK2 932/4885MAOA 4536/4885MAOB 4468/4885 |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | LRRK2 1899/4885MAOA 1126/4885MAOB 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.